IP Library › Granted Patent US 12668773
Granted Patent B2
US 12668773 · App. 17/783,598 · Granted Jun 30, 2026

Production method for organoid

Inventors: Kentaro Shoji (Tokyo, JP); Toshiro Sato (Tokyo, JP)
Assignees: JSR Corporation; KEIO UNIVERSITY
C12N5/06C07K14/4743C07K14/485C07K14/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12668773
App. No.
17/783,598
Filed
Jun 8, 2022
Granted
Jun 30, 2026
Kind
B2
Art Unit
1634
USPC
435/325
Abstract

A production method for an organoid, the production method including a step of culturing adult stem cells or a cell tissue piece including adult stem cells in a medium containing a chimeric Fibroblast Growth Factor (FGF) that includes a partial region of FGF1 and a partial region of FGF2; an organoid produced by the production method; a medium including a chimeric FGF and having a content of chimeric FGF of 50 ng/mL or less; and an evaluation method for a test substance are provided, and according to the chimeric FGF, a content of growth factors included in a medium can be reduced.

Claims (25)

1 . A production method for an organoid, the method comprising:

culturing adult stem cells or a stem cell tissue piece including adult stem cells in a medium comprising a chimeric Fibroblast Growth Factor (FGF) having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

2 . The production method according to claim 1 ,

wherein a content of the chimeric FGF included in the medium is 50 ng/ml or less.

3 . The production method according to claim 1 ,

wherein the medium further comprises Epidermal Growth Factor (EGF).

4 . The production method according to claim 3 ,

wherein a total content of the chimeric FGF and the EGF included in the medium is 100 ng/ml or less.

5 . The production method according to claim 1 ,

wherein the medium further contains comprises an Insulin-like growth factor (IGF) signaling pathway promoter.

6 . The production method according to claim 1 ,

wherein the medium further comprises a Transforming Growth Factor-β (TGF-β) signaling pathway inhibitor.

7 . The production method according to claim 1 ,

wherein the medium further comprises a Wnt signaling pathway promoter.

8 . The production method according to claim 1 ,

wherein the medium further comprises a Rho-kinase (ROCK) signaling pathway inhibitor.

9 . The production method according to claim 1 ,

wherein the medium further comprises a Bone morphogenetic protein (BMP) signaling pathway inhibitor.

10 . A medium comprising a chimeric FGF,

wherein the chimeric FGF is a protein having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, and

wherein a content of the chimeric FGF is 50 ng/ml or less.

11 . The medium according to claim 10 ,

wherein the medium further comprises EGF, and a total content of the chimeric FGF and the EGF is 100 ng/ml or less.

12 . A chimeric FGF, wherein the chimeric FGF is a protein having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

13 . The production method according to claim 1 , wherein the adult stem cells are epithelial stem cells.